Mutant human insulin receptor DNA
AssigneesOtsuka Pharmaceutical Co., Ltd., Yousuke Ebina
InventorYousuke Ebina
Life of this patent
Estimating the term…
Abstract
A mutant human insulin receptor DNA, wherein the base sequence encoding Thr.sup.831 in human insulin receptor DNA has been replaced by a base sequence encoding Ala and/or the base sequence encoding Tyr.sup.1334 therein has been replaced by a base sequence encoding Cys; a fragment of the mutant human insulin receptor DNA containing the mutation part(s); a diagnostic probe for non-insulin-dependent diabetes mellitus comprising this fragment; and a diagnostic drug for non-insulin-dependent diabetes mellitus containing this fragment.
Claims11
A mutant human insulin receptor DNA, wherein the base sequence encoding Thr.sup.831 in human insulin receptor DNA has been replaced by a base sequence encoding Ala and/or the base sequence encoding Tyr.sup.1334 therein has been replaced by a base sequence encoding Cys, or a fragment of said mutant human insulin receptor DNA containing the mutation, comprising the base sequence encoding Ala and/or the base sequence encoding Cys.
A method for diagnosing non-insulin-dependent diabetes mellitus, comprising the steps of:
- (a) amplifying a DNA region containing the base sequence encoding Thr.sup.831 and/or Tyr.sup.1334 in human insulin receptor DNA from a nucleic acid sample obtained from a subject;
- and
- (b) detecting a mutation of the base sequence in said DNA region, wherein the mutation is such that the base sequence encoding Thr.sup.831 has been replaced by a base sequence encoding Ala and/or the base sequence encoding Tyr.sup.1334 has been replaced by a base sequence encoding Cys and wherein the mutation is diagnostic for non-insulin-dependent diabetes mellitus.
Dependencies are inferred from the claim text.